Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Immunotherapy

Hope Against All Odds: My Journey with Immunotherapy for Advanced Bladder Cancer
Michael Morigi shares his very positive experience with immunotherapy in the treatment of his stage III bladder cancer. Read More ›

Immunotherapy a Safe Option in Immunocompromised Patients with Advanced Skin Cancer
Immunotherapy is showing good results in patients with advanced skin cancer, one of the most common types of cancer diagnosed in the United States. Read More ›

Immunotherapy Brings New Hope for Patients with Non–Small-Cell Lung Cancer and PD-1/PD-L1 Biomarker
Two experts discuss the advances made in lung cancer with the introduction of new immunotherapies, which have extended life for patients, and why testing for biomarkers is crucial. Read More ›

Jemperli First Immunotherapy FDA Approved for Endometrial Cancer with dMMR Biomarker
In April 2021, the FDA approved Jemperli (dostarlimab-gxly) for patients with recurrent or advanced endometrial cancer and the biomarker mismatch repair-deficient. This is the first immunotherapy approved for patients with this type of cancer. Read More ›

Opdivo First Immunotherapy Approved for First-Line Therapy of Gastric Cancers
In April 2021, the FDA approved Opdivo (nivolumab), for use with chemotherapy, as first-line treatment for patients with advanced or metastatic gastric cancer, including gastroesophageal junction cancer and esophageal adenocarcinoma. Read More ›

Keytruda Another Immunotherapy Approved for First-Line Treatment of Advanced Gastric Cancer
In May 2021, the FDA approved Keytruda (pembrolizumab), plus Herceptin and chemotherapy, for first-line treatment of locally advanced unresectable or metastatic, HER2-positive gastric or gastroesophageal junction adenocarcinoma. Keytruda is the second immunotherapy approved for gastric cancer. Read More ›

Is It Breast or Skin Cancer? How a Misdiagnosis Shaped My Cancer Journey
Chris Andersen learned the value of trusting one’s instincts and asking for a second opinion after receiving a misdiagnosis of breast cancer that was later diagnosed as metastatic skin cancer and she was told she had 1 to 2 years to live. Thanks to a new treatment for skin cancer, she now has no signs of cancer. Read More ›

Immunotherapy for the Management of Triple-Negative Metastatic Breast Cancer

Libtayo Reduces Pain, Improves Quality of Life  in Patients with Advanced Cutaneous  Squamous-Cell Carcinoma
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer. Read More ›

Immunotherapy: Innovating the Way We Treat Cancer
Dive into this special issue focused on immunotherapy, the innovative methods of treating cancer today, with this introduction by Lillie Shockney, RN, BS, MAS, HON-ONN-CG. Read More ›

Page 2 of 7